RT @Crit_Care: #CritCare #OpenAccess #Gershengorn HB: The delicate equilibrium between #innovation and #evidence https://t.co/ZblD9uCZbF…
@rupert_pearse @remap_cap @AcuteCareTrials @msh_manu @HBGMD writes eloquently on the challenge in @Crit_Care https://t.co/OYfoNTyhm0
Early adoption of critical care interventions is unjustifiable without concomitant effectiveness study | Critical Care | Full Text https://t.co/CxK1ZoRwQT
RT @Crit_Care: #CritCare #OpenAccess #Gershengorn HB: The delicate equilibrium between #innovation and #evidence https://t.co/ZblD9uCZbF…
RT @Crit_Care: #CritCare #OpenAccess #Gershengorn HB: The delicate equilibrium between #innovation and #evidence https://t.co/ZblD9uCZbF…
RT @Crit_Care: #CritCare #OpenAccess #Gershengorn HB: The delicate equilibrium between #innovation and #evidence https://t.co/ZblD9uCZbF…
RT @Crit_Care: #CritCare #OpenAccess #Gershengorn HB: The delicate equilibrium between #innovation and #evidence https://t.co/ZblD9uCZbF…
#CritCare #OpenAccess #Gershengorn HB: The delicate equilibrium between #innovation and #evidence https://t.co/ZblD9uCZbF #FOAMed #FOAMcc #BMC #ICU #Sars_CoV_2 #early_adoption #guidelines #therapy @jlvincen @ISICEM https://t.co/EgtNCgxrmI